3:
Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.
J Clin Oncol. 2007 Nov 20;25(33):5194-202. Epub 2007 Oct 22.
PMID: 17954712 [PubMed - indexed for MEDLINE]
Related Articles
6:
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.
Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D.
Ann Oncol. 2007 May;18(5):851-8. Epub 2007 Feb 14. Erratum in: Ann Oncol. 2007 Nov;18(11):1916.
PMID: 17301075 [PubMed - indexed for MEDLINE]
Related Articles
7:
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V.
Breast Cancer Res. 2006;8(4):R36.
PMID: 16846533 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
10:
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernández R, Tusquets I, Gil M, Barnadas A, Constenla M, Gilabert M, Alba E.
Cancer. 2007 Nov 15;110(10):2178-85.
PMID: 17926331 [PubMed - indexed for MEDLINE]
Related Articles
12:
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.
Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V.
Clin Breast Cancer. 2007 Feb;7(6):471-9.
PMID: 17386124 [PubMed - indexed for MEDLINE]
Related Articles
13:
Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulias V, Mavroudis D.
Clin Breast Cancer. 2007 Dec;7(11):883-9.
PMID: 18269779 [PubMed - indexed for MEDLINE]
Related Articles
17:
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.
Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, Rulli A, Crinò L.
Ann Oncol. 2008 May;19(5):883-90. Epub 2008 Jan 10.
PMID: 18187484 [PubMed - indexed for MEDLINE]
Related Articles
18:
Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D.
Clin Cancer Res. 2008 May 1;14(9):2593-600.
PMID: 18451221 [PubMed - indexed for MEDLINE]
Related Articles
19:
Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
Anticancer Res. 2004 May-Jun;24(3b):2061-8.
PMID: 15274401 [PubMed - indexed for MEDLINE]
Related Articles